Pretreatment Staging FDG PET-Derived Radiomic Score Predicts Progression-Free Survival in Locally Advanced Rectal...

Background/Objectives: Clinical outcomes in locally advanced rectal cancer (LARC) treated with total neoadjuvant therapy (TNT) remain heterogeneous, and available clinicopathological parameters provide limited prognostic accuracy. This study aimed to develop a radiomic score (RadScore) from baseline staging 18F-FDG PET/CT images using LASSO-penalized Cox regression, and to evaluate its ability to independently predict progression-free survival (PFS) in LARC patients treated with TNT followed by surgery. Methods: Eighty-five patients with LARC who underwent surgical resection after TNT between May 2018 and December 2024 were retrospectively analyzed. Primary tumor volumes were semi-automatically segmented on pretreatment FDG PET/CT images, and 140 radiomic features were extracted in accordance with Image Biomarker Standardisation Initiative (IBSI) guidelines. After correlation-based filtering, 23 non-redundant features were subjected to five-fold cross-validated LASSO-Cox regression for feature selection and RadScore construction. Internal validation used 1000-repetition bootstrap resampling. Results: Disease progression was recorded in 33 of 85 patients (mean PFS: 57.5 months). The final RadScore comprised two features-Intensity Histogram Kurtosis and GLCM Difference Entropy-and was identified as an independent prognostic factor in multivariable Cox analysis (HR = 1.81; 95% CI: 1.23-2.67; p = 0.003). The model achieved a C-index of 0.674, with a bootstrap-corrected C-index of 0.650 (95% CI: 0.568-0.741). Kaplan-Meier analysis demonstrated significantly shorter PFS in the high-risk group (log-rank p = 0.006). Conclusions: A pretreatment FDG PET-derived RadScore independently predicts PFS in LARC patients treated within a TNT framework, offering preliminary evidence for a potential imaging biomarker for preoperative risk stratification and individualized treatment planning-to our knowledge, among the first such evidence in a TNT-treated rectal cancer cohort.